iBeam Technology Secures 15 Billion KRW Series C Funding

[Asia Economy Reporter Lee Gwanju] iBeam Technology announced on the 21st that it has secured 15 billion KRW in Series C funding.

This Series C round included participation from LB Investment, Premier Partners, BNH Investment, Atinum Investment, Timefolio Asset Management, and Mirae Asset Venture Investment. Among iBeam Technology's existing investors, LB Investment, BNH Investment, Atinum Investment, Timefolio Asset Management, and Mirae Asset Venture Investment made follow-up investments.

iBeam Technology, a faculty startup from the Graduate School of Medical Science and Engineering at KAIST, achieved 3 billion KRW in Series A funding just three months after its founding in 2017, followed by 8 billion KRW in Series B funding in 2019. Including the current Series C funding, the company has recorded a total cumulative investment of 26 billion KRW. iBeam Technology is the first in the world to develop and successfully commercialize a biomicroscope capable of directly observing living cells inside biological organs.

Kim Pilhan, CEO of iBeam Technology, stated, “The smooth completion of this funding round reflects recognition of iBeam Technology’s core technology and expertise in biomicroscope development.” He added, “With this investment fueling our growth, iBeam Technology will accelerate its leap to become a global market leader through differentiated biomicroscope development and expansion into AI medical devices.”

This content was produced with the assistance of AI translation services.